These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23284648)

  • 1. R&D incentives for neglected diseases.
    Dimitri N
    PLoS One; 2012; 7(12):e50835. PubMed ID: 23284648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R&D investments for neglected diseases can be sensitive to the economic goal of pharmaceutical companies.
    Dimitri N
    Drug Discov Today; 2012 Aug; 17(15-16):818-23. PubMed ID: 22414544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economics of priority review vouchers.
    Dimitri N
    Drug Discov Today; 2010 Nov; 15(21-22):887-91. PubMed ID: 20732445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on stimulating industrial research and development for neglected infectious diseases.
    Webber D; Kremer M
    Bull World Health Organ; 2001; 79(8):735-41. PubMed ID: 11545330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Encouraging the development of new vaccines.
    Grabowski H
    Health Aff (Millwood); 2005; 24(3):697-700. PubMed ID: 15886162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should financial incentives be used to differentially reward 'me-too' and innovative drugs?
    Pekarsky B
    Pharmacoeconomics; 2010; 28(1):1-17. PubMed ID: 20014872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Building local research and development capacity for the prevention and cure of neglected diseases: the case of India.
    Kettler HE; Modi R
    Bull World Health Organ; 2001; 79(8):742-7. PubMed ID: 11545331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fostering innovative product development for neglected tropical diseases through partnerships.
    Starr A; Graef KM; Dent J
    Pharm Pat Anal; 2016 Sep; 5(6):391-400. PubMed ID: 27813447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spurring new research for neglected diseases.
    Anderson GF
    Health Aff (Millwood); 2009; 28(6):1750-9. PubMed ID: 19887416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of product subsidies on R&D investment for new energy vehicle firms: Considering quality preference of the early adopter group.
    Meng W; Wang Y; Li Y; Huang B
    PLoS One; 2020; 15(7):e0236626. PubMed ID: 32735570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neglected infectious diseases: are push and pull incentive mechanisms suitable for promoting drug development research?
    Mueller-Langer F
    Health Econ Policy Law; 2013 Apr; 8(2):185-208. PubMed ID: 23343639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of case studies evaluating economic incentives to promote occupational safety and health.
    Elsler D; Treutlein D; Rydlewska I; Frusteri L; Krüger H; Veerman T; Eeckelaert L; Roskams N; Van Den Broek K; Taylor TN
    Scand J Work Environ Health; 2010 Jun; 36(4):289-98. PubMed ID: 20523960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance.
    Årdal C; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2017 Oct; 65(8):1378-1382. PubMed ID: 29017240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating putative repellent 'push' and attractive 'pull' components for manipulating the odour orientation of host-seeking malaria vectors in the peri-domestic space.
    Njoroge MM; Fillinger U; Saddler A; Moore S; Takken W; van Loon JJA; Hiscox A
    Parasit Vectors; 2021 Jan; 14(1):42. PubMed ID: 33430963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expert Delphi survey on research and development into drugs for neglected diseases.
    Fehr A; Thürmann P; Razum O
    BMC Health Serv Res; 2011 Nov; 11():312. PubMed ID: 22087801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incentives for Starting Small Companies Focused on Rare and Neglected Diseases.
    Ekins S; Wood J
    Pharm Res; 2016 Apr; 33(4):809-15. PubMed ID: 26666772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of financial incentives on the quality of health care provided by primary care physicians.
    Scott A; Sivey P; Ait Ouakrim D; Willenberg L; Naccarella L; Furler J; Young D
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008451. PubMed ID: 21901722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incentives, health promotion and equality.
    Voigt K
    Health Econ Policy Law; 2012 Jul; 7(3):263-83. PubMed ID: 20854723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. R&D in Vaccines Targeting Neglected Diseases: An Exploratory Case Study Considering Funding for Preventive Tuberculosis Vaccine Development from 2007 to 2014.
    Costa Barbosa Bessa T; Santos de Aragão E; Medeiros Guimarães JM; de Araújo Almeida B
    Biomed Res Int; 2017; 2017():4765719. PubMed ID: 28133608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perceptions of Financial Incentives for Smoking Cessation: A Survey of Smokers in a Country With an Endgame Goal.
    Robertson L; Gendall P; Hoek J; Marsh L; McGee R
    Nicotine Tob Res; 2018 Nov; 20(12):1481-1488. PubMed ID: 29253215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.